YORK, England and GAITHERSBURG, Md., Oct. 19, 2006: Xceleron, the global leader in ultra-sensitive analysis techniques for the acceleration of drug development, announced today that it has brought in two new members to expand its scientific advisory board (SAB) under the chairmanship of Professor Malcolm Rowland. The board’s role is to advise the company on further developing its core drug development technologies and joining Professor Malcolm Rowland on the SAB will be pharmaceutical industry experts Dr Richard Jones and Dr Roy Bullingham.
